Provided by Tiger Trade Technology Pte. Ltd.

Arin Tactical Tail Risk ETF

95.04
+0.13830.15%
Post-market: 95.040.00000.00%16:10 EDT
Volume:1K
Turnover:102.26K
Market Cap:107.32M
PE:- -
High:95.04
Open:95.03
Low:95.03
Close:94.90
52wk High:95.30
52wk Low:45.10
Shares:1.13M
Float Shares:1.13M
Volume Ratio:0.10
T/O Rate:0.10%
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

The Bond Selloff is Rattling Investors, but Here's Why They Shouldn't Expect a Deeper Stock Downturn

Dow Jones
·
Aug 19

Banco Santander receives Federal Reserve approval for Webster acquisition

TIPRANKS
·
Aug 05

A Federal Reserve Stuck in Limbo

Dow Jones
·
Jul 31

Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks

Benzinga Earnings
·
Jul 31

Southbound 2x Long Nikkei ETF (07262) Drops Over 5% Intraday as Korean Index Plunge Fuels Market Risk Aversion

Stock News
·
Jul 29

Risk Aversion Fades, USD/JPY Holds High-Level Consolidation

Deep News
·
Jul 27

Surge in Oil Prices Stirs Rate Hike Fears; US Bond Yields Climb, Wall Street Sounds Correction Alarm

Stock News
·
Jul 25

Market Risk Aversion Eases, US Dollar Index Ends Slightly Lower

Deep News
·
Jul 23

Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune

GlobeNewswire
·
Jul 22

Alnylam Pharmaceuticals (ALNY) Could Be 28% Undervalued Following Rival ATTR Trial Failure

Simply Wall St.
·
Jul 10

Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM

GlobeNewswire
·
Jul 02

DKSH Partners with BridgeBio to Distribute ATTR-CM Drug in Key Asia-Pacific Markets

TIPRANKS
·
Jun 11

AstraZeneca Advances Dual ATTR-CM Therapy With New Phase IIb Trial

TIPRANKS
·
Jun 11

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

GlobeNewswire
·
May 11

BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil

GlobeNewswire
·
May 06

AstraZeneca Targets Early Detection in China With New ATTR Heart Disease Study

TIPRANKS
·
Apr 15

Assessing BridgeBio Pharma (BBIO) Valuation After Key ATTR-CM And LGMD2I/R9 Milestones

Simply Wall St.
·
Apr 13

BridgeBio: Advancing First-in-Class LGMD Therapy and Blockbuster ATTR Franchise Underpin Reiterated Buy and $100 Target

TIPRANKS
·
Mar 31

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

GlobeNewswire
·
Mar 31

Alnylam Pharmaceuticals: Durable ATTR Growth and Amvuttra Momentum Support Buy Rating and Upside Potential

TIPRANKS
·
Mar 25